- PRECISION1 for Astigmatism, born from Water Gradient
Technology, features the proven PRECISION BALANCE 8|4 lens design
for a stable contact lens-wearing experience1-3
- The lens offers a significant opportunity to attract new
contact lens wearers and reduce contact lens dropouts
- PRECISION1 and PRECISION1 for Astigmatism are now widely
available in the U.S. and will roll out concurrently worldwide
beginning in February 2021
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210119006202/en/
PRECISION1® for Astigmatism Logo
(Graphic: Business Wire)
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, announced the U.S. launch of
PRECISION1® for Astigmatism, a daily disposable, silicone hydrogel
(SiHy) contact lens designed for astigmatic patients.
“PRECISION1, with its cutting-edge SMARTSURFACE® technology, has
become the fastest-growing daily disposable contact lens brand in
the U.S.,” said Sergio Duplan, President, Alcon North America. “We
are thrilled to build on this momentum by introducing PRECISION1
for Astigmatism, Alcon’s first daily disposable, SiHy toric lens at
a mainstream price. This innovation offers Eye Care Professionals a
lens for more of their astigmatic patients to start in and stay
in.”
PRECISION1 for Astigmatism, born from the Water Gradient
Technology of DAILIES TOTAL1®, features the proven PRECISION
BALANCE 8|4® lens design for a stable lens-wearing experience.1-3
Clinical studies show the toric lens settles in less than 60
seconds and 3º of ideal orientation for a 99% first fit success
rate.2* Additionally, a single 6 o’clock scribe mark makes fitting
exceptionally easy.2
Astigmatism is a common vision problem caused by an irregularly
shaped cornea. This can cause images to blur or stretch out. Alcon
estimates that toric lenses, which correct for astigmatism,
represent 23% of the $9 billion global contact lens market.4 As a
result, there is a significant opportunity to attract new contact
lens wearers and reduce lens dropouts. For example, studies show
that 41% of patients are astigmatic,5 but only 10% wear toric
contact lenses.6 Further, about 65% of contact lens dropouts have
astigmatism.6
Born from Water Gradient Technology, PRECISION1 lenses feature
SMARTSURFACE Technology, a permanent micro-thin, high-performance
layer of moisture that steps up from 51% water at the core to
greater than 80% water at the outer surface.7 These lenses support
a stable tear film to deliver lasting performance.7
“Many of my patients want long-lasting comfort from their daily
disposable contact lens, and that’s led me to wholeheartedly
prescribe PRECISION1,” said Aaron Luekenga, OD, Heritage Valley Eye
Care, California.** “Now with PRECISION1 for Astigmatism, I can
offer my astigmatic patients a stable, next-generation lens-wearing
experience.”
PRECISION1 and PRECISION1 for Astigmatism are available in
optical retailers/practices and online throughout the United
States. Eye Care Professionals, with or without fit sets, will have
access to order trial and revenue lenses directly from Alcon or an
Alcon-authorized distributor.
In addition, PRECISION1 and PRECISION1 for Astigmatism will
begin to roll out concurrently worldwide beginning in February
2021.
For more information, visit www.Precision1.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
References
^Trademarks are the property of their respective owners.
*Based on lens movement, centration and rotation at initial
fitting.
**Dr. Luekenga is a paid consultant for Alcon.
- Alcon data on File, 2019.
- Alcon data on File, 2020 (n=78 eyes).
- In a randomized, subject-masked, multi-site study with over 150
patients; significance demonstrated at the 0.05 level; Alcon data
on file, 2005.
- Alcon Estimates and independent market research.
- Luensmann, D., Contact Lens and Anterior Eye (2018).
- Multi-Sponsor Surveys 2014 Gallup target market report.
- Alcon data on file, 2019.
- Based on share growth, private practice sales, Q1-Q3 2020; ABB
Analyze powered by GLIMPSE.
- Private practice sales, on average, Q1-Q3 2020; ABB Analyze
powered by GLIMPSE.
- Miller J, Giedd B, Subbaraman L. Clinical comparison of
verofilcon A and etafilcon A daily disposable contact lenses.
Poster presented at virtual American Academy of Optometry 2020
annual meeting; October 7 - 22, 2020.
Connect with us on
Facebook
LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119006202/en/
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 213 280 9974 (Fort Worth)
globalmedia.relations@alcon.com Investor
Relations Christina Cheng + 41 589 112 110 (Geneva) + 1
817 615 2789 (Fort Worth) investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024